cGMP-Aligned · FDA-Registered U.S. Facility · Third-Party COA on Every LotSupplied for Research Use Only
BioRegenEx · Research

MSC Exosomes for Autism Spectrum Disorder | BioRegenEx

← Back to Research Library

Emerging research suggests MSC-derived exosomes may modulate neuroinflammation and immune dysregulation — two key pathways implicated in autism spectrum disorder (ASD). BioRegenEx supplies research-grade MSC exosomes exclusively to licensed physicians exploring regenerative approaches to ASD.

✔ PubMed Verified Studies✔ FDA-Registered Supplier✔ Physician-Only Access

Autism and Neuroinflammation: The Biological Case for Exosomes

Autism spectrum disorder (ASD) affects approximately 1 in 36 children in the United States. While ASD is complex and multifactorial, a growing body of research points to chronic neuroinflammation, immune dysregulation, and oxidative stress as significant contributing factors — all areas where MSC-derived exosomes have demonstrated measurable effects in published research.

Because exosomes can cross the blood-brain barrier and deliver anti-inflammatory signaling molecules directly to neural tissue, they represent a novel avenue of investigation for physicians working in regenerative and integrative medicine.

Published Research: MSC Exosomes and Autism

The BioRegenEx research library includes 5 peer-reviewed studies on exosome activity relevant to autism spectrum disorder. Key published findings include:

How MSC Exosomes May Support ASD-Related Pathways

  • Neuroinflammation reduction: MSC exosomes carry anti-inflammatory cytokines and microRNA sequences that suppress pro-inflammatory signaling in the CNS.
  • Immune modulation: Research shows exosome cargo can shift immune profiles from pro-inflammatory Th1/Th17 states toward regulatory T-cell activity.
  • Oxidative stress reduction: Several studies demonstrate exosome-mediated upregulation of antioxidant pathways in neural tissue.
  • Gut-brain axis: Emerging research points to exosome effects on gut microbiome composition, which is increasingly implicated in ASD pathophysiology.

Why Physicians Choose BioRegenEx for ASD Research

  • FDA-registered, cGMP-manufactured MSC exosomes with documented potency and purity
  • Full research documentation to support clinical decision-making
  • Access to 248 peer-reviewed studies organized by condition at bioregenex.com/research
  • Dedicated physician support team for protocol guidance

Partner With BioRegenEx

Join licensed physicians across the US who use BioRegenEx research-grade MSC exosomes in their regenerative medicine practice.

Request Physician Portal Access

Important Information

These statements have not been evaluated by the U.S. Food and Drug Administration. BioRegenEx products are not intended to diagnose, treat, cure, or prevent any disease.

Exosome therapy is an emerging regenerative approach. It is investigational, outcomes vary, and individual results cannot be guaranteed. Patient testimonials reflect individual experiences and are not representative of typical results.

References to regulatory standards — including Section 351(a) of the Public Health Service Act — describe the company’s stated quality and compliance approach and should not be interpreted as FDA approval or endorsement of any product.

This presentation is provided for educational and informational purposes only and does not constitute medical advice. Treatment decisions should always be made in consultation with a qualified, licensed healthcare provider.